Tolerability of dose escalation of ibandronate in patients with multiple myeloma and end-stage renal disease: a case series.
Bone disease is a feature of multiple myeloma (MM). Many patients have compromised renal function and sometimes develop end-stage renal disease (ESRD). For these patients, presently there exists no approved bisphosphonate, which is an elementary part of the standard therapeutic regimen of MM. We evaluated the tolerability of ibandronate 2-6 mg every 4 weeks in patients with MM and ESRD receiving regular hemodialysis over 12 weeks (open-label, single-center, observational study). Ibandronate pharmacokinetics were measured until the end of the next dialysis. Adverse events were recorded. 8 patients received ibandronate (average duration 5.6 months). Urinary excretion ranged from 0.15 to 341.9 microg/24 h. Mean ibandronate peak levels increased in a dose-dependent manner (2 mg: 141.4 +/- 67.0 ng/ml; 4 mg: 298.5 +/- 82.0 ng/ ml; 6 mg: 564.3 +/- 318.9 ng/ml). No adverse events were reported. Based on these results and published bisphosphonate data, we have decided to offer off-label ibandronate treatment to MM patients receiving hemodialysis.